LHLyndal Henden

Lyndal Henden

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lyndal Henden has a total of 247 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identity-by-descent to resolve reduced penetrance and advance gene discovery in neurodegenerative disease

    by Lyndal Henden, Sandrine Chan Moi Fat, Andrew Smith, Isabel Li, Thomas J Nicholas, Miran Mrkela, Daniel O'SHaughnessy, Zoe Zussa, Natalie Grima, Emily P McCann, et al.

    Advances in sequencing technologies have transformed human genetics and accelerated disease gene discovery. Yet a causal mutation remains to be identified for many families with an inherited disease. Incomplete penetrance, genetic heterogeneity and limited family history can complicate the binary classification of familial and sporadic disease. These challenges are amplified in late-onset diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), where obscured inheritance patterns limit gene discovery opportunities and can confound clinical risk assessment. We evaluated whether identity-by-descent (IBD) analysis can uncover cryptic relatedness and mitigate the impact of incomplete penetrance on disease gene mapping and clinical interpretation. Genome-wide IBD inference was performed in an integrated cross-continent cohort of 3524 individuals of European ancestry spanning the ALS-FTD neurodegenerative spectrum. IBD identified 793 pairs of 1st–6th degree relatives (siblings to second cousins once removed), of which 31.5% were previously unrecognized and 15.8% had differing clinical diagnoses. Among individuals recorded as ‘sporadic’, 5.5% of ALS and 15.9% of FTD were genetically related to another affected individual in the cohort, demonstrating that reduced penetrance masks a substantial proportion of heritable disease. Affected individuals with known ALS/FTD-associated genetic variants had balanced male-to-female ratios, irrespective of reported family history or IBD-inferred relatedness, whereas those without an identified disease-linked genetic variant retained the expected male predominance in ALS/FTD cohorts. IBD analysis identified multiple cross-continent founder networks for known ALS disease genes, including SOD1 and C9orf72, and created 73 new IBD-defined pedigrees from apparently unrelated probands, providing a framework for disease variant discovery in otherwise underpowered families. Using SOD1 mutation-positive families as a positive-control framework, we demonstrated that IBD-based pedigree expansion retained the known disease locus in distant relatives while reducing genome-wide candidate regions, supporting its application to unresolved ALS/FTD pedigrees. In an IBD-identified extended pedigree comprising five affected individuals, genome-wide variant filtering identified three rare variants within a chromosome 13q21.33 candidate locus shared IBD by four individuals and supported by multipoint linkage analysis. IBD-based detection of cryptic relatedness reveals genetic links between familial and apparent sporadic neurodegenerative disease, helping to resolve penetrance-related inheritance misclassification. By reconstructing extended pedigrees using IBD, this approach strengthens gene discovery and supports variant pathogenicity while providing clinicians with clearer context for inherited risk and genetic counselling.

  • Open Access

    Characterising the motif composition and allele length distribution of ZFHX3 GGC repeat expansions in amyotrophic lateral sclerosis

    by Zoe N. Zussa, Andrew N. Smith, Joke J.F.A van Vugt, Daniel S. O’SHaughnessy, Natalie Grima, Sandrine Chan Moi Fat, Ian P. Blair, Dominic B. Rowe, Roger Pamphlett, Garth A. Nicholson, et al.

    A pathogenic GGC repeat expansion in zinc finger homeobox 3 ( ZFHX3 ), encoding a pure polyglycine (polyG) tract, causes spinocerebellar ataxia type 4 (SCA4). Intermediate expansions of other SCA loci have been implicated in amyotrophic lateral sclerosis (ALS), while repeat motif composition is recognised to influence pathogenicity in neurodegenerative diseases. Given the genetic pleiotropy between ALS and SCA, we evaluated whether ZFHX3 GGC expansions are associated with ALS and characterised repeat motif composition. ZFHX3 GGC repeat sizes were genotyped using ExpansionHunter in short-read whole-genome sequencing data from ALS cases and healthy controls of European ancestry. Repeat sizes were visually inspected using REViewer, and motif configurations were manually derived from a subset. Receiver operating characteristic analysis and Youden’s J statistic identified a candidate repeat size threshold. Logistic regression tested associations of repeat length and motif composition with ALS, while regression models assessed clinical phenotypes. Across 5785 ALS cases and 7982 controls, no association was observed between ZFHX3 expansions and ALS risk. Longer alleles showed a nominal association with later disease onset, however this did not remain significant after Bonferroni correction. Among 802 ALS cases and 800 controls, 50 distinct motif compositions were identified, including 11 encoding pure polyG tracts characteristic of pathogenic SCA4 expansions; none were associated with ALS. Although no association with ALS was observed, this study established the dynamic nature of ZFHX3 repeat motif composition and configuration. Variation within and between repeat sizes, including pure polyG repeats, supports consideration of motif composition alongside allele length when evaluating neurodegenerative disease risk.

  • Open Access

    Motor neuron disease in rural Australia: a population-based observational study of epidemiology, clinical characteristics and regional variation

    by Amanda L. Wright, Zoe N. Zussa, Sandrine Chan Moi Fat, Carol M. Y. Lee, Louis Christie, Catherine Keniry, Simon Hawke, Dominic B. Rowe, Kelly L. Williams, Lyndal Henden

    Objectives: To characterise the epidemiology, clinical features, and geographic distribution of motor neuron disease (MND) within a rural Australian population. Design: Retrospective, population-based epidemiology study. Setting: Western New South Wales Local Health District (WNSWLHD), Australia, from 1 January 2023 to 31 December 2025. Participants: Fifty-one individuals diagnosed with MND identified through Central West Neurology and Neurosurgery, Orange Palliative Care Service, and the WNSWLHD Neurodegenerative Community Care Team. Main outcome measures: Crude and age-standardised incidence, prevalence and mortality rates of MND; demographic and clinical characteristics; geographic distribution of prevalence. Results: The all-age crude incidence of MND was 4.01 per 100,000 person-years (95% CI, 2.78-5.60), prevalence was 8.14 per 100,000 population (95% CI, 6.33-10.30), and mortality was 3.77 per 100,000 person-years (95% CI, 2.58-5.33). Females comprised 51% of patients and showed higher incidence, prevalence and mortality than males. Bulbar-onset MND accounted for 47% of patients, including 61% of females. MND prevalence varied across the health district, with the highest burden observed in central and south-eastern regional areas. Patients travelled on average 139 km to access neurological care, with a diagnostic delay of nine months. Conclusions: MND incidence and mortality are high in this rural Australian population compared with national and global estimates, with an overrepresentation of bulbar-onset disease and altered sex distribution. These findings provide an important baseline for population-level MND surveillance, following the introduction of mandatory notification in NSW, Australia. Findings also highlight the need for strengthened rural healthcare services, and further research of potential genetic and environmental contributors to MND risk.

  • Open Access

    Characterising the motif composition and allele length distribution of ZFHX3 GGC repeat expansions in amyotrophic lateral sclerosis

    by Zoe N. Zussa, Andrew N. Smith, Joke J.F.A van Vugt, Daniel S. O’SHaughnessy, Natalie Grima, Sandrine Chan Moi Fat, Ian P. Blair, Dominic B Rowe, Roger Pamphlett, Garth A Nicolson, et al.

    Background and objectives: A pathogenic GGC repeat expansion in the zinc finger homeobox 3 ( ZFHX3 ) gene, encoding a pure polyglycine tract, is the cause of spinocerebellar ataxia type 4 (SCA4). Intermediate expansions of other SCA loci contribute to the risk of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease involving the progressive loss of motor neurons. There is increasing awareness of the role of short tandem repeat (STR) motif composition and configuration in disease pathogenicity. Given the genetic pleiotropy between ALS and SCA, this study aimed to evaluate whether ZFHX3 GGC expansions were associated with ALS and to characterise repeat motif composition. Methods: ExpansionHunter v5 was used to genotype ZFHX3 GGC repeat sizes in short-read whole genome sequencing data from people with ALS and healthy controls of European ancestry. Repeat sizes were visually inspected using REViewer v2. Repeat motif configurations of Australian ALS cases and healthy controls were manually derived from REViewer images. Receiver operating characteristic (ROC) curve analysis and Youden’s J statistic were performed to find a candidate repeat size threshold for association testing. Fisher’s exact tests were performed to evaluate the associations of repeat size and motif composition with disease status. Results: Analysis of 5,785 people with ALS and 7,982 healthy controls found no association between ZFHX3 GGC repeat expansions and disease risk. Fifty unique repeat motif compositions were identified across 802 people with ALS and 800 healthy controls. Of these, eleven distinct configurations coded a pure polyglycine tract which, when expanded, is canonical to SCA4, though no association with ALS was found. Discussion: Although no association was observed between ZFHX3 GGC repeat expansions and ALS, this study established the dynamic nature of ZFHX3 repeat motif composition and configuration. Unique motif compositions were identified both within and between repeat sizes, including the presence of pure polyglycine repeats. Consideration of repeat motif composition and configuration, in addition to repeat allele length, may be important for assessing neurodegenerative disease risk.

  • Open Access

    Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement

    by Natalie Grima, Andrew N. Smith, Claire E. Shepherd, Lyndal Henden, Thiri Zaw, Luke Carroll, Dominic B. Rowe, Matthew C. Kiernan, Ian P. Blair, Kelly L. Williams

    Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that primarily affects the motor neurons, causing progressive muscle weakness and paralysis. While research has focused on understanding pathological mechanisms in the motor cortex and spinal cord, there is growing evidence that extra-motor brain regions may also play a role in the pathogenesis or progression of ALS. Methods: We generated 165 sample-matched post-mortem brain transcriptomes from 22 sporadic ALS patients with pTDP-43 pathological staging and 11 non-neurological controls. For each individual, five brain regions underwent mRNA sequencing: motor cortex (pTDP-43 inclusions always present), prefrontal cortex and hippocampus (pTDP-43 inclusions sometimes present), and occipital cortex and cerebellum (pTDP-43 inclusions rarely present). We examined gene expression, cell-type composition, transcript usage (% contribution of a transcript to total gene expression) and alternative splicing, comparing ALS-specific changes between brain regions. We also considered whether post-mortem pTDP-43 pathological stage classification defined ALS subgroups with distinct gene expression profiles. Results: Significant gene expression changes were observed in ALS cases for all five brain regions, with the cerebellum demonstrating the largest number of total (> 3,000) and unique (60%) differentially expressed genes. Pathway enrichment and predicted activity were largely concordant across brain regions, suggesting that ALS-linked mechanisms, including inflammation, mitochondrial dysfunction and oxidative stress, are also dysregulated in non-motor brain regions. Switches in transcript usage were identified for a small set of genes including increased usage of a POLDIP3 transcript, associated with TDP-43 loss-of-function, in the cerebellum and a XBP1 transcript, indicative of unfolded protein response activity, in the motor cortex. Extensive variation in RNA splicing was identified in the ALS brain, with 26–41% of alternatively spliced genes unique to a given brain region. This included detection of TDP-43-associated cryptic splicing events such as the STMN2 cryptic exon which was shown to have a pTDP-43 pathology-specific expression pattern. Finally, ALS patients with stage 4 pTDP-43 pathology demonstrated distinct gene and protein expression changes in the cerebellum. Conclusions: Together our findings highlighted widespread transcriptome alterations in ALS post-mortem brain and showed that, despite the absence of pTDP-43 pathology in the cerebellum, extensive and pTDP-43 pathological stage-specific RNA changes are evident in this brain region.


  • Open Access

    Author Correction: The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration

    by Sarah Opie-Martin, Alfredo Iacoangeli, Simon D. Topp, Olubunmi Abel, Keith Mayl, Puja R. Mehta, Aleksey Shatunov, Isabella Fogh, Harry Bowles, Naomi Limbachiya, et al.


  • Open Access

    Short tandem repeat expansions in LRP12 are absent in cohorts of familial and sporadic amyotrophic lateral sclerosis patients of European ancestry

    by Lyndal Henden, Liam G. Fearnley, Dean Southwood, Andrew Smith, Dominic B. Rowe, Matthew C. Kiernan, Roger Pamphlett, Melanie Bahlo, Ian P. Blair, Kelly L. Williams

    In patients of Asian ancestry, a heterozygous CGG repeat expansion of >100 units in LRP12 is the cause of oculopharyngodistal myopathy type 1 (OPDM1). Repeat lengths of between 61 and 100 units have been associated with rare amyotrophic lateral sclerosis (ALS) cases of Asian ancestry, although with unusually long disease duration and without significant upper motor neuron involvement. This study sought to determine whether LRP12 CGG repeat expansions were also present in ALS patients of European ancestry. Whole-genome sequencing data from 608 sporadic ALS patients, 35 familial ALS probands, and 4703 neurologically normal controls were screened for LRP12 CGG expansions using ExpansionHunter v4. All individuals had LRP12 CGG repeat lengths within the normal range of 3-25 units. To date, LRP12 CGG repeat expansions have not been reported in ALS patients of European ancestry and may be limited to rare ALS patients of Asian ancestry and atypical clinical presentations.


  • Open Access

    Hippocampal aggregation signatures of pathogenic UBQLN2 in amyotrophic lateral sclerosis and frontotemporal dementia

    by Kyrah M Thumbadoo, Birger V Dieriks, Helen C Murray, Molly E V Swanson, Ji Hun Yoo, Nasim F Mehrabi, Clinton Turner, Michael Dragunow, Richard L M Faull, Maurice A Curtis, et al.

    Pathogenic variants in the UBQLN2 gene cause X-linked dominant amyotrophic lateral sclerosis and/or frontotemporal dementia characterised by ubiquilin 2 aggregates in neurons of the motor cortex, hippocampus, and spinal cord. However, ubiquilin 2 neuropathology is also seen in sporadic and familial amyotrophic lateral sclerosis and/or frontotemporal dementia cases not caused by UBQLN2 pathogenic variants, particularly C9orf72-linked cases. This makes the mechanistic role of mutant ubiquilin 2 protein and the value of ubiquilin 2 pathology for predicting genotype unclear. Here we examine a cohort of 44 genotypically diverse amyotrophic lateral sclerosis cases with or without frontotemporal dementia, including eight cases with UBQLN2 variants (resulting in p.S222G, p.P497H, p.P506S, p.T487I (two cases), and p.P497L (three cases)). Using multiplexed (5-label) fluorescent immunohistochemistry, we mapped the co-localisation of ubiquilin 2 with phosphorylated TDP-43, dipeptide repeat aggregates, and p62, in the hippocampus of controls (n = 6), or amyotrophic lateral sclerosis with or without frontotemporal dementia in sporadic (n = 20), unknown familial (n = 3), SOD1-linked (n = 1), FUS-linked (n = 1), C9orf72-linked (n = 5), and UBQLN2-linked (n = 8) cases. We differentiate between i) ubiquilin 2 aggregation together with phosphorylated TDP-43 or dipeptide repeat proteins, and ii) ubiquilin 2 self-aggregation promoted by UBQLN2 pathogenic variants that cause amyotrophic lateral sclerosis/and frontotemporal dementia. Overall, we describe a hippocampal protein aggregation signature that fully distinguishes mutant from wildtype ubiquilin 2 in amyotrophic lateral sclerosis with or without frontotemporal dementia, whereby mutant ubiquilin 2 is more prone than wildtype to aggregate independently of driving factors. This neuropathological signature can be used to assess the pathogenicity of UBQLN2 gene variants and to understand the mechanisms of UBQLN2-linked disease.


  • Open Access

    RNA sequencing of peripheral blood in amyotrophic lateral sclerosis reveals distinct molecular subtypes: Considerations for biomarker discovery

    by Natalie Grima, Sidong Liu, Dean Southwood, Lyndal Henden, Andrew Smith, Albert Lee, Dominic B. Rowe, Susan D'SIlva, Ian P. Blair, Kelly L. Williams

    Aim: Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative disease with limited therapeutic options. A key factor limiting the development of effective therapeutics is the lack of disease biomarkers. We sought to assess whether biomarkers for diagnosis, prognosis or cohort stratification could be identified by RNA sequencing (RNA‐seq) of ALS patient peripheral blood.Methods: Whole blood RNA‐seq data were generated for 96 Australian sporadic ALS (sALS) cases and 48 healthy controls (NCBI GEO accession GSE234297). Differences in sALS–control gene expression, transcript usage and predicted leukocyte proportions were assessed, with pathway analysis used to predict the activity state of biological processes. Weighted Gene Co‐expression Network Analysis (WGCNA) and machine learning algorithms were applied to search for diagnostic and prognostic gene expression patterns. Unsupervised clustering analysis was employed to determine whether sALS patient subgroups could be detected.Results: Two hundred and forty‐five differentially expressed genes were identified in sALS patients relative to controls, with enrichment of immune, metabolic and stress‐related pathways. sALS patients also demonstrated switches in transcript usage across a small set of genes. We established a classification model that distinguished sALS patients from controls with an accuracy of 78% (sensitivity: 79%, specificity: 75%) using the expression of 20 genes. Clustering analysis identified four patient subgroups with gene expression signatures and immune cell proportions reflective of distinct peripheral effects.Conclusions: Our findings suggest that peripheral blood RNA‐seq can identify diagnostic biomarkers and distinguish molecular subtypes of sALS patients however, its prognostic value requires further investigation.